Menu
  • About RedHill
  • Products
  • Partnering
  • Investors
  • News
  • Contact
  • CAREERS
  • Press Releases

    Date Summary View
    Toggle Summary RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S.
    Esomeprazole Strontium Delayed-Release (DR) Capsules 49.3 mg is an FDA -approved, proprietary, prescription proton pump inhibitor (PPI) indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal ( GI) conditions   PPIs are one of the most commonly ...
    View HTML
    Toggle Summary RedHill Biopharma to Present at the 10th Annual BioPharm America International Partnering Conference
    TEL-AVIV, Israel and RALEIGH, N.C. , Sept. 07, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of ...
    View HTML
    Toggle Summary RedHill Biopharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
    TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 31, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, ...
    View HTML
    Toggle Summary RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules
    RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. ...
    View HTML
    Toggle Summary RedHill Biopharma Provides 2017 Semi-Annual Business Update
    RedHill Biopharma Provides 2017 Semi-Annual Business Update RedHill's U.S. gastrointestinal (GI)-focused sales force is promoting two specialty products, setting the stage for the potential launch of RedHill's late clinical-stage GI products, if approved, and for the acquisition of additional ...
    View HTML
    Toggle Summary RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn's Disease
    The independent Data and Safety Monitoring Board (DSMB) reviewed safety and efficacy data, of which RedHill remains blinded, from the first 222 subjects who have completed week 26 assessments in the Phase III MAP US study   To date, over 300 of the planned 410 subjects, have been randomized in the ...
    View HTML
    Toggle Summary RedHill Biopharma Reports 2017 Second Quarter Financial Results
    RedHill maintains a debt-free balance sheet with $51 million cash 1  at the end of the second quarter of 2017  Select recent milestones include: Initial net revenues of approximately $0.5 million between June 12-30 following commencement of promotional activities in the U.S. ...
    View HTML
    Toggle Summary RedHill Biopharma to Host Second Quarter 2017 Financial Results Conference Call on July 25, 2017
    TEL-AVIV, Israel and RALEIGH, N.C. , July 18, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, ...
    View HTML
    Toggle Summary RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D
    Top-line results are expected in September 2017 The randomized, double-blind, placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDA ®  (RHB-102) 12 mg in 127 U.S. patients with diarrhea-predominant irritable bowel syndrome (IBS-D),   with a primary endpoint of ...
    View HTML
    Toggle Summary RedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn's Disease
    The second independent Data and Safety Monitoring Board (DSMB) meeting of the RHB-104 Phase III study for Crohn's disease (MAP US study) is planned to be held in late July 2017 and will assess the safety and efficacy of RHB-104 in the first 222 subjects who have completed week 26 assessments The ...
    View HTML